Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

World Clinical Trials Racial Representation Data Study 2022 Featuring Novartis, GSK, Pfizer, Johnson & Johnson, AstraZeneca, F. Hoffmann-La Roche, Eli Lilly, Merck & Co, AbbVie, & Bayer
By: PR Newswire Association LLC. - 23 Nov 2022Back to overview list

DUBLIN, Nov. 23, 2022 /PRNewswire/ -- The "Clinical Trials - The Importance of Diversity in Clinical Trials" report has been added to  ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

This report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trials sectors to highlight the level of diversity.

The clinical trials data used for these analyses was extracted from the publisher's Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022.

Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement.

Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included.

Reasons to Buy

  • Provides a breakdown of racial representation data across a number of clinical trial sectors.
  • Identifies which areas are lacking in clinical trial population diversity.
  • Highlights the variation in diversity in the industry and against institutional sponsors.
  • Documents the barriers to diversity in clinical trials and outlines steps to improve it.
  • Assesses how decentralized and virtual components in clinical trials affect diversity.

Key Topics Covered:

  • Executive Summary
  • Introduction
  • Analysis of Diversity in Clinical Trials (2013-2022)
  • Key Findings
  • Appendix

Companies Mentioned

  • Novartis
  • GSK
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Eli Lilly
  • Merck & Co
  • AbbVie
  • Bayer

For more information about this report visit https://www.researchandmarkets.com/r/7qavq9

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

 

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

 

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

 

Cision View original content:https://www.prnewswire.com/news-releases/world-clinical-trials-racial-representation-data-study-2022-featuring-novartis-gsk-pfizer-johnson--johnson-astrazeneca-f-hoffmann-la-roche-eli-lilly-merck--co-abbvie--bayer-301686003.html

SOURCE Research and Markets

Copyright 2022 PR Newswire Association LLC. Back to overview list
to the top ↑